Maravai LifeSciences (NASDAQ:MRVI) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Maravai LifeSciences (NASDAQ:MRVI) issued its quarterly earnings data on Wednesday. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03, FiscalAI reports. The business had revenue of $45.85 million during the quarter, compared to analysts’ expectations of $43.56 million. Maravai LifeSciences had a negative return on equity of 15.70% and a negative net margin of 37.07%.

Here are the key takeaways from Maravai LifeSciences’ conference call:

• Q3 revenue rose 10% to $45.9 million, led by mRNA growth of 28% (GMP consumables +30%, discovery mRNA +27%). Cygnus grew 8%, marking its sixth consecutive quarter of year-over-year growth.
• Adjusted EBITDA improved by $16.6 million year over year to $5.8 million, and Maravai raised its 2026 revenue outlook to $212–$216 million and adjusted EBITDA outlook to $40–$42 million.
• Management cited a healthy mRNA pipeline and growing customer adoption: 10 discovery customers transitioned to clinical-stage GMP year to date, surpassing the company’s target of nine, and more than 180 customers are using ModTail.
• Management cautioned that GMP and CDMO orders are program-driven and can vary significantly by quarter; it expects GMP activity to skew toward the second half of 2027 and does not anticipate substantial 2027 GMP revenue from ModTail. Specialty chemistry revenue also declined 4% as large prior-year orders did not repeat.

Maravai LifeSciences Trading Down 9.0%

Shares of NASDAQ MRVI traded down $0.70 during midday trading on Thursday, reaching $7.02. The stock had a trading volume of 2,309,760 shares, compared to its average volume of 2,478,056. The company’s 50 day moving average price is $7.42 and its 200 day moving average price is $5.29. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.98 and a current ratio of 4.05. Maravai LifeSciences has a twelve month low of $2.55 and a twelve month high of $9.42. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -13.55 and a beta of 0.61.

Analyst Ratings Changes

Several analysts recently commented on the stock. TD Cowen started coverage on shares of Maravai LifeSciences in a report on Monday, October 5th. They set a “buy” rating and a $9.00 price target for the company. UBS Group upped their price objective on shares of Maravai LifeSciences from $2.50 to $8.00 and gave the company a “neutral” rating in a research note on Wednesday, September 9th. Wells Fargo & Company increased their target price on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a research note on Wednesday, August 26th. Finally, Wall Street Zen cut Maravai LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 29th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Maravai LifeSciences presently has a consensus rating of “Moderate Buy” and an average target price of $7.38.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc is a life sciences company that provides products and services used in the development, manufacture and quality testing of biopharmaceuticals, vaccines and diagnostic products. The company serves pharmaceutical, biotechnology, academic and other research organizations involved in nucleic acid and biologics development.

Through its TriLink BioTechnologies business, Maravai supplies specialized nucleic acid products and services, including modified nucleotides, messenger RNA-related materials, enzymes and other components used in research and biomanufacturing.